var data={"title":"Insulin degludec: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Insulin degludec: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/788620?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=insulin-degludec-drug-information\" class=\"drug drug_general\">see &quot;Insulin degludec: Drug information&quot;</a> and <a href=\"topic.htm?path=insulin-degludec-patient-drug-information\" class=\"drug drug_patient\">see &quot;Insulin degludec: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50707933\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Insulin Pen Safety Alert</span>\n      <span class=\"collapsible-date\">October 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Institute for Safe Medication Practices (ISMP) National Medication Errors Reporting Program (MERP) has issued a safety alert regarding reports of patients incorrectly using insulin pens at home, resulting in severe cases of hyperglycemia. Patients were not removing the inner cover of a standard insulin pen needle prior to attempting to administer the insulin, and thus were not receiving insulin doses.</p>\n        <p style=\"text-indent:0em;\">Health care professionals should instruct patients on the proper use of insulin pens and require patient demonstration to verify understanding. They should also verify which pen needles patients will be using at home, either standard pens or pens with automatic needle retraction devices, and tailor instruction accordingly.</p>\n        <p style=\"text-indent:0em;\">More information can be found at http://www.ismp.org/NAN/files/NAN-20171012.pdf.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45600791\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tresiba FlexTouch</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50606318\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tresiba</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49417385\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Insulin, Long-Acting</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49491768\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=insulin-degludec-drug-information\" class=\"drug drug_general\">see &quot;Insulin degludec: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">The general objective of insulin replacement therapy is to approximate the physiologic pattern of insulin secretion. This requires a basal level of insulin throughout the day, supplemented by additional insulin at mealtimes. Since combinations using different types of insulins are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. The frequency of doses and monitoring must be individualized in consideration of the patient's ability to manage therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin degludec is a long-acting insulin administered by SubQ injection. When compared to insulin regular, insulin degludec has a slower onset and a longer duration of activity. Changing the basal insulin component from another insulin to insulin degludec requires a dose reduction to minimize the risk of hypoglycemia. Insulin requirements vary dramatically between patients and dictates frequent monitoring and close medical supervision.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note: </b>U-200 FlexTouch pens do not allow odd numbered dosing of insulin units; patients requiring odd numbered doses should use the U-100 FlexTouch pen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Type 1 diabetes mellitus:</b> Children and Adolescents: <b>Note:</b> Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the <b>total units/kg/day of all insulin formulations</b> used. Insulin degludec must be used in combination with a short-acting insulin.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>General insulin dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Usual maintenance range:</i> SubQ: 0.5 to 1 unit/kg/day in divided doses; doses must be individualized; however, an estimate can be determined based on phase of diabetes and level of maturity (ISPAD [Couper 2014]; ISPAD [Danne 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Partial remission phase (Honeymoon phase): &lt;0.5 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Prepubertal children (not in partial remission): 0.7 to 1 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1.2 unit/kg/day and in some cases up to 2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i> Division of daily insulin requirement (&quot;conventional therapy&quot;):</i> Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Division of daily insulin requirement (&quot;intensive therapy&quot;):</i> Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adjustment of dose:</i> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Insulin degludec-specific dosing:</b> Children and Adolescents: SubQ: <b>Note:</b> Not recommended for patients requiring less than 5 units of insulin degludec.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Insulin-naive patients: </i>Approximately one-third to one-half of the total daily insulin requirement administered as insulin degludec once daily; remainder of total daily dose should be given as a short- or rapid-acting insulin and divided between each daily meal (general rule for initial total daily insulin dose: 0.2 to 0.4 units/kg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Insulin<i>-experienced patients: </i></i>Initiate insulin degludec at 80% of the total daily long- or intermediate-acting insulin unit dose from which the patient is being converted.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustment: </i>Individualize and titrate dose every 3 to 4 days based on patient&rsquo;s metabolic needs, blood glucose monitoring results, and glycemic control goal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Type 2 diabetes mellitus:</b> Children &ge;10 years and Adolescents:<b> Note: </b>Not recommended for patients requiring less than 5 units of insulin degludec.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>General insulin dosing: </b>SubQ: The goal of therapy is to achieve an HbA1c &lt;6.5% as quickly as possible using the safe titration of medications. Initial therapy in metabolically unstable patients (eg, plasma glucose &ge;250 mg/dL, HbA1c &gt;9% and symptoms excluding acidosis) may include once daily intermediate acting insulin or basal insulin in combination with lifestyle changes and metformin. In patients who fail to achieve glycemic goals with metformin and basal insulin, may consider initiating prandial insulin (regular insulin or rapid acting insulin) and titrate to achieve goals. Once initial goal reached, insulin should be slowly tapered and the patient transitioned to lowest effective doses or metformin monotherapy if able (AAP [Copeland 2013]; ISPAD [Zeitler 2014]). <b>Note:</b> Patients who are ketotic or present with ketoacidosis require aggressive management as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Insulin degludec-specific dosing: Note: </b>Not recommended for patients requiring less than 5 units of insulin degludec.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Insulin-naive patients:</i> Initial: 10 units once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Insulin-experienced patients: </i>Initiate insulin degludec at 80% of the total daily long- or intermediate-acting insulin unit dose from which the patient is being converted</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustment: </i>Individualize and titrate dose every 3 to 4 days based on patient&rsquo;s metabolic needs, blood glucose monitoring results, and glycemic control goal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes mellitus, type 1:</b> <b>Note:</b> Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of different insulin formulations are commonly used. The daily doses presented below are expressed as the <b>total units/kg/day of all insulin formulations combined.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>General insulin dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial total insulin dose:</i> SubQ: 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapid-acting insulin may be the only insulin formulation used initially.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Usual maintenance range:</i> SubQ: 0.5 to 1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Nonobese: 0.4 to 0.6 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Obese: 0.8 to 1.2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Division of daily insulin requirement (&ldquo;conventional therapy&rdquo;): </i>Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate-acting (eg, NPH) or a long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting or short-acting form of insulin.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Division of daily insulin requirement (&ldquo;intensive therapy&rdquo;):</i> Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of short- or rapid-acting insulin (eg, insulin aspart) formulations 3 or more times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adjustment of dose:</i> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Because combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen that most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Insulin degludec-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Insulin-naive:</i> SubQ: Initial: One-third to one-half the total daily insulin dose given as insulin degludec administered once daily; remainder of total daily dose should be given as a short- or rapid-acting insulin and divided between each daily meal (general rule for total daily dose, 0.2 to 0.4 units/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Insulin-experienced:</i> SubQ: Initiate with same unit dose as the total daily long or intermediate-acting insulin unit dose from which the patient is being converted.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustment:</i> Individualize and titrate dose every 3 to 4 days based on patient&rsquo;s metabolic needs, blood glucose monitoring results, and glycemic control goal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes mellitus, type 2:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>General considerations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Timing of initiation:</i> The goal of therapy is to achieve an HbA<sub>1c</sub> &lt;7%. According to a position statement by the ADA and European Association for the Study of Diabetes (EASD), dual therapy (metformin + a second antihyperglycemic agent) is recommended in patients with type 2 diabetes who fail to achieve glycemic goals after ~3 months with lifestyle interventions and metformin monotherapy (unless contraindications to metformin exist). Preference is not given for adding insulin or a noninsulin agent as the second antihyperglycemic agent (drug choice should be individualized based on patient characteristics). However, insulin should be considered as part of a combination regimen when hyperglycemia is severe, particularly if patient is symptomatic or has catabolic features (eg, weight loss, ketosis). If insulin is selected, the addition of <b>basal</b> insulin (ie, a long-acting insulin such as glargine, degludec, or detemir) at 10 units (or 0.1 to 0.2 units/kg) once daily is recommended. If HbA<sub>1c</sub> target not achieved after ~3 months of dual therapy, may proceed to triple therapy (Inzucchi 2015). If HbA<sub>1c</sub> &gt;8% prior to initiation of basal insulin, 0.2 to 0.3 units/kg once daily is recommended (AACE/ACE [Garber 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Intensification of therapy:</i> If HbA<sub>1c</sub> target has not been met, despite titrating <b>basal</b> insulin (ie, long-acting insulin) to provide acceptable fasting blood glucose concentrations, intensification of therapy should be considered to cover postprandial glucose excursions. Options include adding a mealtime insulin (1 to 3 injections of a rapid-acting insulin analog [lispro, aspart, glulisine]) <b>or</b> adding a GLP-1 receptor agonist (eg, exenatide, liraglutide). Alternatively, although less studied, may transition from basal insulin (ie, long-acting insulin) to a twice daily premixed (or biphasic) insulin analog (70/30 aspart mix, 75/25 or 50/50 lispro mix) (Inzucchi 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Insulin degludec-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Insulin-naive:</i> Initial: 10 units once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Insulin-experienced:</i> Initiate with same unit dose as the total daily long or intermediate-acting insulin unit dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustment: </i>Individualize and titrate dose every 3 to 4 days based on patient&rsquo;s metabolic needs, blood glucose monitoring results, and glycemic control goal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Missed dose:</b> Administer as soon as possible; ensure at least 8 hours between consecutive doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45600792\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tresiba FlexTouch: 100 units/mL (3 mL); 200 units/mL (3 mL) [contains metacresol, phenol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45600790\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49417388\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: SubQ: Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles. Administer subcutaneously into the thigh, upper arm, or abdomen, with sites rotated to decrease the risk of lipodystrophy; do not administer IM or IV, or in an insulin infusion pump. Administer once daily, at any time of day, but at the same time each day in pediatric patients. In adults, insulin degludec should be administered once daily at any time of the day. Do not dilute or mix insulin degludec with any other insulin formulation or solution; do not transfer from the FlexTouch pen into a syringe for administration. Do not perform dose conversion when using the FlexTouch pen. The dose window for both U-100 and U-200 FlexTouch pens show the number of insulin units to be delivered and no conversion is needed. U-200 FlexTouch pens do not allow odd numbered dosing of insulin units; patients requiring odd numbered doses should use the U-100 FlexTouch pen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45671911\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store not in use (unopened) pens at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) until expiration date, or at room temperature below 30&deg;C (86&deg;F) for up to 56 days (8 weeks). Do not freeze or use if solution has been frozen. Do not store pens directly adjacent to the refrigerator cooling element.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store in use (opened) pens at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or at room temperature (below 30&deg;C [86&deg;F]) for up to 56 days (8 weeks); protect from direct heat and light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49417386\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of diabetes mellitus (type 1 or type 2) to improve glycemic control (FDA approved in ages &ge;1 year and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45671905\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tresiba may be confused with Tarceva</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes insulins among its classes of drugs which have a heightened risk of causing significant patient harm when used in error. <b><i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Insulin degludec is a clear solution, but it is <b>NOT</b> intended for IV or IM administration.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">U-200 FlexTouch pens do not allow odd numbered dosing of insulin units; patients requiring odd numbered doses should be prescribed the U-100 FlexTouch pen.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45359160\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Antibody development (may necessitate dose adjustments), hypokalemia, severe hypoglycemia (more common in type 1 diabetics on combination insulin therapy), weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (type 2 diabetes), gastroenteritis (type 1 diabetes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (including discoloration, erythema, hematoma, hemorrhage, mass, nodules, pain, pruritus)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasopharyngitis, sinusitis (type 1 diabetes: 5%), upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but imporant or life-threatening: Hypersensitivity reaction, hypertrophy at injection site (lipohypertrophy), lipoatrophy at injection site, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45027420\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to insulin degludec or any component of the formulation; during episodes of hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for insulin is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45671909\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe, life-threatening allergic reactions, including anaphylaxis, may occur. If hypersensitivity reactions occur, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage or even death. Insulin requirements may be altered during illness, emotional disturbances or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetic ketoacidosis: Should not be used in patients with diabetic ketoacidosis (DKA); use of an IV rapid acting or short acting insulin is preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen (insulin regular) in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, <b>basal </b>insulin or <b>basal</b> plus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of <b>basal </b>insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2017d).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: A decrease in glucose lowering effect of insulin degludec with increasing body mass index (BMI) has been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Insulin degludec is a clear solution, but it is <b>NOT</b> intended for IV or IM administration or via an insulin pump.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin), insulin administered via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45116817\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45116814\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=112048&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the hypoglycemic effect of Insulins.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving  both basal insulin and a sulfonylurea.<b> Exceptions: </b>Liraglutide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: If liraglutide is used for the treatment of diabetes (Victoza), consider insulin dose reductions. The combination of liraglutide and insulin should be avoided if liraglutide is used exclusively for weight loss (Saxenda).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45671907\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies secondary to maternal hypoglycemia.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013; Lambert 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28 to 32 weeks' gestation. Following delivery, insulin requirements decrease rapidly (ACOG 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018c). Information specific to insulin degludec use in pregnant women is limited (Milluzzo 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49417389\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma glucose, urine glucose, electrolytes, HbA<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change (ADA 2017), lipid profile, renal function, hepatic function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49417390\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Plasma Blood Glucose and HbA<sub>1c</sub> Goals for Diabetes Patients (ADA 2017):</b> Goals should be individualized based on individual needs/circumstances (eg, patients who experience severe hypoglycemia, patients with hypoglycemic unawareness); lower goals may be reasonable if they can be achieved without excessive hypoglycemia. <b>Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the &quot;peak.&quot;</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial glucose: 90 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime/overnight glucose: 90 to 150 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (&lt;7% is reasonable if it can be achieved without excessive hypoglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults, nonpregnant:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postprandial glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45671913\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Insulin degludec differs from human insulin by the omission of the amino acid threonine in position B-30 of the B-chain, and the subsequent addition of a side chain composed of glutamic acid and a C16 fatty acid. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin degludec is a long-acting, human insulin analog.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45671915\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99% (albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~25 hours (independent of dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 9 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45762883\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Tresiba FlexTouch Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $110.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 units/mL (3 mL): $221.57</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45040525\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Tregludec (IL);</li>\n      <li>Tresiba (AE, AR, AT, CH, CR, CY, CZ, DE, DK, DO, EE, ES, FI, GB, GR, GT, HK, HN, HR, HU, IE, IN, IS, JP, KR, LB, LT, LU, MT, NI, NL, NO, PA, PH, PL, PT, SE, SI, SK, SV, TR, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2005;105(3):675-685.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/23969827/pubmed\" target=\"_blank\" id=\"23969827\">23969827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 12. Management of diabetes in pregnancy.<i> Diabetes Care</i>. 2016d;39(Suppl 1):S94-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/26696688 /pubmed\" target=\"_blank\" id=\"26696688 \">26696688 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979900\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy. <i>Diabetes Care</i>. 2017c;40(suppl 1):S114-S119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/27979900/pubmed\" target=\"_blank\" id=\"27979900\">27979900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). Standards of medical care in diabetes 2017. <i>Diabetes Care</i>. 2017;40(Suppl 1):S1-135.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/24194617/pubmed\" target=\"_blank\" id=\"24194617\">24194617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couper JJ, Haller MJ, Ziegler AG, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Phases of type 1 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2014;15(Suppl 20):18-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/25325095/pubmed\" target=\"_blank\" id=\"25325095\">25325095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Danne T, Bangstad HJ, Deeb L, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2014;15(Suppl 20):115-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/25182312/pubmed\" target=\"_blank\" id=\"25182312\">25182312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garber AJ, Abrahamson MJ, Barzilay JI. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2016 Executive Summary. <i>Endocr Pract</i>. 2016;22(1):84-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/26731084/pubmed\" target=\"_blank\" id=\"26731084\">26731084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al, &quot;Hyperglycemia and Adverse Pregnancy Outcomes,&quot; <i>N Engl J Med</i>, 2008, 358(19):1991-2002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/18463375/pubmed\" target=\"_blank\" id=\"18463375\">18463375</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Association of Diabetes and Pregnancy Study Groups Consensus Panel (IADPSG), Metzger BE, Gabbe SG, et al, &quot;International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy,&quot; <i>Diabetes Care</i>, 2010, 33(3):676-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/20190296/pubmed\" target=\"_blank\" id=\"20190296\">20190296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i>. 2015;38(1):140-149.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/25538310/pubmed\" target=\"_blank\" id=\"25538310\">25538310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. <i>Diabetes Care</i>. 2008;31(5):1060-1079.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert K, Holt RI. The use of insulin analogues in pregnancy. <i>Diabetes Obes Metab</i>. 2013;15(10):888-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/23489521/pubmed\" target=\"_blank\" id=\"23489521\">23489521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. <i>Diabetes Care</i>. 2007;30(Suppl 2):251-260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/15461903/pubmed\" target=\"_blank\" id=\"15461903\">15461903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tresiba (insulin degludec) [prescribing information]. Plainsboro, NJ: Novo Nordisk; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-degludec-pediatric-drug-information/abstract-text/22500167/pubmed\" target=\"_blank\" id=\"22500167\">22500167</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 112048 Version 23.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50707933\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45600791\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50606318\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F49417385\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F49491768\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45600792\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F45600790\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49417388\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45671911\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F49417386\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45671905\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45359160\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45027420\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45671909\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45116817\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45116814\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45671907\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F49417389\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F49417390\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45671913\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F45671915\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45762883\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45040525\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/112048|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=insulin-degludec-drug-information\" class=\"drug drug_general\">Insulin degludec: Drug information</a></li><li><a href=\"topic.htm?path=insulin-degludec-patient-drug-information\" class=\"drug drug_patient\">Insulin degludec: Patient drug information</a></li></ul></div></div>","javascript":null}